Adjunctive Platelet-Rich Plasma (PRP) in Infrabony Regenerative Treatment: A Systematic Review and RCT's Meta-Analysis by Saleem, Mubashir et al.
Review Article
Adjunctive Platelet-Rich Plasma (PRP) in Infrabony Regenerative
Treatment: A Systematic Review and RCT’s Meta-Analysis
Mubashir Saleem,1 Flavio Pisani ,1 Faisal Maqbool Zahid,2 Ioannis Georgakopoulos,3
Teuta Pustina-Krasniqi ,4 Edit Xhajanka,5 and Maher Almasri1
1Faculty of Dentistry, School of Health, MClinDent in Periodontology, BPP University Birmingham, Birmingham, UK
2Department of Statistics, Ludwig-Maximilians-University Munich, Munich, Germany
3World Academy of Growth Factors and Stem Cells in Dentistry, Athens, Greece
4Universiteti I Prishtines “Hasan Prishtina”, Prishtine, Kosovo
5Universiteti I Mjekesise Dentare, Tirane, Albania
Correspondence should be addressed to Flavio Pisani; ﬂaviopisani@bpp.com
Received 25 November 2017; Accepted 11 January 2018; Published 19 March 2018
Academic Editor: Marc L. Turner
Copyright © 2018 Mubashir Saleem et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background and Objective. The purpose of this study was to highlight the clinical performance of platelet-rich plasma (PRP) used as
an adjunctive tool for regeneration in infrabony periodontal defects using diﬀerent biomaterials or performing diﬀerent surgical
ﬂap approaches. Comparative evaluation of main clinical outcomes as probing pocket depth reduction, clinical attachment gain,
and recession reduction with and without the use of PRP has been analysed. Materials and Methods. According to the focused
question, an electronic and hand searching has been performed up to December 2016. From a batch of 73 articles, the selection
strategy and Jadad quality assessment led us to include 15 studies for the meta-analysis. Results. Despite the high heterogeneity
found and the lack of complete data regarding the selected clinical outcomes, a comparative analysis has been possible by the
categorization of used biomaterials and surgical ﬂap approaches. This method led us to observe the best performance of grafts
with the use of adjunctive PRP in CAL gain and PPD reduction. No diﬀerence has been outlined with a speciﬁc surgical ﬂap.
Conclusions. Although PRP is considered a cheap and patient’s derived growth factor, the not conclusive data reported would
suggest that its use in addition to bone substitutes could be of some clinical beneﬁt in the regenerative treatment of infrabony
defects. Clinical Relevance. This systematic review was intended to sort out the huge controversial debate in the ﬁeld about the
possible use of PRP in regenerative surgery in infrabony defect. The clinical relevance of using blood-borne growth factors to
conventional procedures is eﬀective as these could determine a better performance and outcomes despite the surgical approach
adopted and limit the use of additional biomaterials for the blood clot stabilization.
1. Introduction
The ultimate goal of periodontal therapy in the case of infrab-
ony defects is regeneration. Regeneration means “reproduc-
tion or reconstitution of a lost or injured part. It takes into
account all the procedures attempting to regenerate lost
periodontal structures through diﬀerential tissue responses
and by diﬀerent biomaterials such as grafts, membranes or
Biomodulators as Enamel Matrix Proteins” (Glossary of
Periodontal Terms, AAP, 2001). These procedures would
temporarily delay the apical migration of the gingival epithe-
lium allowing the granulation tissue derived from the
periodontal ligament and osseous tissue to repopulate the
space adjacent to the denuded root surface [1].
Several materials are available in daily practice, but
none can be considered as an ideal one. In order to
achieve a successful regeneration, biomaterials should fulﬁl
four main characteristics: (1) structural integrity, (2) to
work as a scaﬀold for tissue ingrowth, (3) favoured by
stem cells that can potentially diﬀerentiate and support
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the regeneration, and (4) contain factors for regeneration
and/or repair.
Growth factors (GFs) are expressed during diﬀerent
phases of healing, and they are key elements in promoting
regeneration of tissues; these are considered the most
relevant factors in osseoregenerative process.
Platelet-rich plasma (PRP) is considered a cheap way to
obtain many growth factors (GFs) in physiological propor-
tion, and it has already been largely applied as a GF’s carrier
in diﬀerent tissues due to its properties of inducing healing
response even in cases with low potential [2].
Substantially, PRP is a blood derivate growth factor
with a higher platelet concentration up to 338% that can
release all polypeptide GFs from alpha granules: platelet-
derived growth factor (PDGF), transforming growth fac-
tor-β1 and transforming growth factor-β2 (TGF-β1 and
TGF-β2), and insulin-like growth factors 1 and 2 (IGF-
1,2) [3].
In clinical dental practice, the eﬀective use of PRP has
been described in sinus grafting procedures [4], alveolar
socket preservation techniques [5], and also as an adjunctive
procedure to support the regenerative process in periodontal
infrabony and furcation defects [6].
Although its clinical beneﬁts have been demonstrated
several times, the adjunctive use of autologous PRP in regen-
erative procedures has produced controversial outcomes
ranging from signiﬁcant to null eﬀects, as demonstrated from
diﬀerent published systematic reviews [3, 7].
This review investigates and updates the clinical eﬃcacy
of PRP when added to grafting materials and/or to mem-
branes or biomodulators in cases of periodontal infrabony
defects in patients with advanced chronic periodontitis.
In particular, it was aimed to highlight the most relevant
clinical outcome changes (vertical pocket probing depth,
vertical clinical attachment level, and the recession) in
GTR coupled with PRP compared to the same procedure
without it. In order to get stronger evidence, a SR on pub-
lished RCTs was chosen.
2. Materials and Methods
2.1. Focused Question. The focused question that this system-
atic review is intending to answer is
“What are the Vertical Probing Pocket Depth Reduc-
tions, the Vertical Clinical Attachment Level Gains and the
Recession Reduction at infra-bony defects at least 6 months
after Regenerative Surgery with the adjunctive use of PRP
as documented in Randomized Clinical Trials, compared to
the same clinical procedures and biomaterials performed
without the use of PRP?”
2.2. Eligibility Criteria for Studies to be Included in This
Review. According to the P.I.C.O system [8], inclusion
criteria were outlined as follows:
2.2.1. Study Population. Studies were limited to human sub-
jects older than 18 years and in good general health, with a
diagnosis of chronic periodontitis and with at least one pair
of specular infrabony defects. Studies considering individuals
with a history of aggressive periodontitis or conducted on
animal models were excluded from our consideration.
2.2.2. Type of Interventions. GTR surgical procedures with
and without PRP will be the interventions considered for
the comparative evaluation. The speciﬁc regenerative
techniques and biomaterials investigated in this study were
(1) autologous bone grafts,
(2) bone substitutes (allogenic, xenogenic, and synthetic
grafts),
(3) barrier membranes (resorbable and not resorbable),
(4) enamel matrix proteins (EMD).
2.2.3. Type of Comparison. Infrabony defects treated by
regenerative surgery with PRP were considered the test
group and compared to the same defects treated by the
same regenerative therapy without PRP that were consid-
ered the control group.
2.2.4. Outcome Measures. Outcome variables considered in
this study were
(i) probing pocket depth reduction (PPDRed mm),
(ii) clinical attachment level gain (CALGain mm),
(iii) recession reduction (RECRed).
These were evaluated as the mean diﬀerence (mm) from
the time of surgery until the end of the evaluation period not
before 6 months.
2.2.5. Types of Studies. To be considered for inclusion in this
review, studies should be randomized controlled clinical
trials (RCTs) only; no cohort studies (CHT) or case-control
studies were included. Case series and case reports studies
were also not considered as they would provide a low
strength of evidence.
2.3. Information Sources. The search has been performed by
the use of the following electronic databases: Pubmed,
Cochrane Oral Library, Embase, and LILACS.
Trial registers have been searched using Current Con-
trolled Trials (http://www.controlled-trials.com/), Clinical-
Trials.gov (http://clinicalTrials.gov/ct2/home) and the
World Health Organization International Trials Registry
Platform search portal (http://www.who.int/trialsearch/
Default.aspx).
Conference abstracts have been searched using the ISI
Web of knowledge (http://isiwebofknowledge.com) and the
Grey literature using Open Grey (http://www.opengrey.eu).
Hand searching included a complete search of Journal of
Periodontology and Journal of Clinical Periodontology up to
December 2016 and bibliographies of all relevant papers and
review articles. In the case of ambiguous or missing data,
experts have been contacted directly.
The search has been performed up to and including
December 2016.
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3. Search Strategy
The following search strategy has been used as a combination
of MeSH terms and free text words:
(i) Intervention and materials: (“PRP” [txt words] OR
“Platelet Rich Plasma” [txt words] OR “Platelet”
[mesh] OR “guided tissue regeneration” [mesh] OR
“periodontal” [all ﬁelds] OR “regeneration [mesh]
OR “guided-tissue-regeneration” [txt words] OR
“GTR” [txt words] OR “periodontal regeneration”
[txt words] OR “Bone ﬁller” [txt words] OR “Autol-
ogous bone grafts” [txt words] OR “Autogenous
bone” [txt words] OR “bone substitutes” [mesh]
OR “allogenic grafts” [txt words] OR “Allografts”
[txt words] OR “xenogenic grafts” [txt words] OR
“xenografts” [mesh] OR “synthetic grafts” [txt
words] OR “Barrier membranes” [txt words] OR
“membranes” [mesh] OR “resorbable membrane”
[txt words] OR “non-resorbable membrane” [txt
words] OR “guided bone regeneration” [txt words]
OR “GBR” [txt words] OR “freeze dried bone
allograft” [txt words] OR “demineralized freeze
dried bone allograft” [txt words] OR “DFDBA” [txt
words] OR “FDBA” [txt words] OR “Bio-Oss” [txt
words] OR “Bio-Oss Collagen” [txt words] OR
“Alloplast” [txt words] OR “tricalciumphosphate”
[txt words] OR “cerasorb” [txt words] OR “Bioglass”
[txt words] OR “polymeric” [txt words] OR “colla-
gen sponge” [txt words] OR “Collagen” [txt words]
OR “Biogide” [txt words] OR “Ossix” [txt words]
OR “Gore tex” [txt words] OR “Enamel Matrix
Proteins” [txt words] OR “Emdogain” [txt words]
OR “EMD” [txt words]);
(ii) Disease: (“periodontal defects” [mesh] OR “peri-
odontal [all ﬁelds] OR “infrabony defects” [txt
words]);
(iii) Study design: (.”randomized clinical trials” [mesh]
OR randomized controlled study” [mesh] OR
“clinical trial” [mesh] OR “cohort study” [mesh]
OR “clinical trial” [mesh] OR “comparative study”
[mesh] OR “systematic review” [mesh] OR “case
control study” [mesh] OR “longitudinal study”
[mesh]).
Adopted ﬁlters have been “humans,” and articles were
published in English language.
3.1. Methods of the Review
3.1.1. Screening and Selection. Initially, titles and abstracts of
all reports were screened independently by two reviewers
(MS and FP). Subsequently, for studies appearing to meet
the inclusion criteria, or for which there were insuﬃcient
data in the title and abstract to make a clear decision, the full
report was obtained and independently assessed by three
reviewers (MS, FP, and MA) to establish whether the study
met the inclusion criteria. Any disagreements were resolved
by discussion among the reviewers. All studies meeting the
inclusion criteria then underwent validity assessment. The
reasons for rejecting studies at this or at subsequent stages
were recorded.
Special attention was paid not to duplicate publications
in order to avoid a likely bigger impact of the same data in
the global result.
3.1.2. Quality Assessment/Risk of Bias. The quality assess-
ment of the included studies was undertaken independently
by two reviewers based on the content of the articles. The
reviewers were blind to the name of the authors, institutions,
and journal titles.
A commonly used three-item, ﬁve-point quality scale was
used to rate the quality of the studies [9]. The minimum score
for the inclusion was 2, and the maximum was 5.
Points were awarded according to the following criteria:
(1) Was the study randomized? If yes, +1 point.
Was the randomization procedure appropriate and
clearly reported in the study? If yes, +1 point. If no, all
points deleted.
(2) Was the study double-blinded? If yes, +1 point.
Was the double-blinding method appropriate and
clearly reported in the study? If yes, +1 point. If no, all
points deleted.
(3) Were the reasons for patient withdrawals and
dropouts described, for each treatment group? If
yes, +1 point.
A separate scoring for quality assessment was obtained
and independently assessed by two reviewers (MS, FP) to
establish whether the study met the quality criteria in order
to reduce the risk of bias. The level of agreement between
the two reviewers was calculated using kappa statistics.
3.1.3. Data Extraction. Two reviewers (MS and FP) indepen-
dently using specially designed data extraction forms
extracted the necessary data.Anydisagreementwas discussed,
and a third reviewer (MA) was consulted when necessary.
Authors of studies were contacted for clariﬁcation or
missing information. Data was excluded until further clariﬁ-
cation could be available or if an agreement could not be
reached. When the results of a study were published more
than once or results were detailed in a number of publica-
tions, the most complete data set was sought from all sources
and included only once.
Using a standard protocol, the following data were
collected from the studies:
(i) name of the authors, date of publication, name of
the journal, and setting;
(ii) details on the study design;
(iii) sample size (number/gender);
(iv) follow-up (months);
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(v) treated infrabony defects (number), position of the
defects (maxillary/mandibular);
(vi) intervention/barrier-augmentation material, soft
tissue closure, eventual antibiotic intake,
reassessment;
(vii) control group: intervention/barrier-augmentation
material;
(viii) clinical attachment level gain (CALgain);
(ix) pocket probing depth reduction (PPDRed);
(x) recession reduction (RECRed).
3.1.4. Heterogeneity Assessment. The statistical heterogeneity
among studies has been assessed in two diﬀerent ways:
Cochran’s Q statistical test [10] and I2 test [11] were applied
to the selected studies. A ﬁxed-eﬀects model was adopted
due to the hypothesis of a population of studies with
similar characteristics.
In the case of high heterogeneity values, subgroups, and
sensitivity, analysis was performed based on
(i) study site (maxillary/mandibular);
(ii) regenerative material/s used (bone graft and/or
resorbable/not resorbable barrier);
(iii) surgical technique used.
3.1.5. Data Synthesis. To summarize and compare studies,
data were displayed as a weighted mean diﬀerence (WMD)
in primary and secondary outcomes. Using this index,
data from articles was directly pooled together (means
and 95% CI).
(i) For dichotomous outcomes, the estimates were
expressed as relative risk ratio (RR) together with
95% CI.
(ii) For continuous outcomes, standardized mean diﬀer-
ences and 95% conﬁdence intervals were used to
summarize the data for each study.
The study-speciﬁc estimates were pooled using the ﬁxed-
eﬀects model (Woolf’s method). If a signiﬁcant heterogeneity
was found, the random eﬀect model result was presented.
Forest plots were created to illustrate the eﬀects of the
diﬀerent studies and the global estimation.
SPSS Statistics™ software was used to perform all analy-
ses. Statistical signiﬁcance has been deﬁned as a p value <0.05.
3.1.6. Sensitivity Analysis and Bias Detection. Sensitivity
analysis was performed excluding each of the studies step
by step from the meta-analysis and evaluating the changes
in the global estimation.
Publication biases were evaluated using a funnel plot and
Egger’s linear regression method.
3.1.7. Final Recommendation. A ﬁnal recommendation will
be extracted from the results of this meta-analysis, consider-
ing their clinical signiﬁcance.
4. Results
4.1. Study Selection. The search identiﬁed 39 articles on a
record of 73 further ﬁltered for “Humans,” “Clinical Trial,”
and “English Language.” The independent screening of the
titles andabstracts led to the rejectionof18papers.The full text
of the remaining 21 papers was then searched. For 1 study, the
full text was not obtained [12], so the ﬁnal pool was 20 studies.
Out of these, 3 papers were further rejected for the following
reasons: two studies did not provide a control group [13, 14]
and one was not a fully RCT [15]. Two articles were rejected
because they did not provide comprehensive data and/or
standard deviations to be analysed [16, 17].
On the ﬁrst screening, agreement between the reviewers
was met for all the articles except one [18], because of the
lab method for PRP gel preparation. The 3rd reviewer solved
the debate by accepting it.
The ﬁnal number of included studies was 15, and their
characteristics are reported in Table 1. Not all the considered
studies reported the mean change and the SD value for each
outcome; in these cases, the studies were excluded from
meta-analysis regarding the missing data (Figure 1).
4.1.1. Classiﬁcation of Studies according to Treatments. The
included studies were grouped according to provided treat-
ment. This action allowed us to analyse better the perfor-
mance of PRP adding in the following test groups:
Group 1: biomodulators versus biomodulators and
PRP (2 articles),
Group 2: grafts versus grafts and PRP (6 articles),
Group 3: none versus PRP alone (1 article),
Group 4: grafts andmembranes versus grafts,membranes,
and PRP (6 articles).
4.2. Methodological Quality of Included Studies. The quality
of the included studies was assessed according to Jadad
scoring [9].
Scoring was independently assessed by the reviewers, and
all the studies reported a minimum of 2 points or above,
allowing them to be included.
To test the extent of interagreement between the two
reviewers, Cohen’s Kappa Statistics was used.
Its value lies between −1 and 1, where 1 is the perfect
agreement, 0 is exactly what would be expected by chance,
and negative values indicate agreement less than chance, that
is, potential systematic disagreement.
The calculated point estimate of Cohen’s kappa statistic κ
was 0.74, which according to the commonly cited scale for
interpretation of kappa statistic (Landis and Koch [33]) indi-
cates a substantial agreement between the two reviewers. The
Z score = 5.77 with p value <.0001 showed that κ is diﬀerent
from zero. The 95% conﬁdence limits for κ were (0.52, 0.97).
4.3. Heterogeneity Assessment. In order to evaluate if a
within-study or between-study variability occurred, hetero-
geneity was assessed. Cochran’s Q test was calculated
although the small number of included studies led to the
consideration of I2 statistics in a ﬁxed-eﬀects model. The I2
statistics showed a substantial heterogeneity for VCAL and
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VPD outcomes, while no heterogeneity was found according
to REC.
4.4. Change in Vertical Clinical Attachment Level (VCAL)
(Closed Assessment). To test the eﬀectiveness of using PRP
in addition to the adopted treatment, 95% conﬁdence inter-
vals were constructed for diﬀerence between the means of
test and control groups. The graphical presentation is
reported in Figure 2. Out of nine articles, results of ﬁve arti-
cles led us to accept the hypothesis of no diﬀerence between
the test and control groups, whereas four articles (Hanna
et al. [31], Okuda et al. [29], Piemontese et al. [25], and
Kaushick et al. [22]) suggested results in favour of the test
group as the SDs showed a mean CAL gain of 2mm com-
pared to the control group.
4.5. Change in Vertical Probing Depth (VPD). Twelve arti-
cles were able to provide data regarding vertical probing
depth (VPD).
Four out of these 12 [23, 26–28] studies showed no diﬀer-
ence between the test and control groups, whereas the
remaining 8 favoured the addition of PRP showing a
VPDRed of about 1.5mm (see Figure 3).
4.6. Change in Recession. Out of 8 articles providing useful
data for analysis, only one [20] seemed to show the eﬀective-
ness of the test group versus the control group in recession
reduction of about 0.5mm after treatment. The other seven
studies did not provide any evaluable diﬀerence between
groups (see Figure 4).
4.7. Change in Clinical Outcomes Regarding Treatment
Groups. According to the categorization of treatments into
4 groups, only 2 of them provided evaluable data regarding
the adopted clinical outcomes: grafts + PRP and grafts
+ PRP+membranes.
Biomodulators and PRP alone included one single eva-
luable observation as the other selected articles did not
provide any mean baseline-ﬁnal VCAL, VPD, and REC
change or the SD.
When comparing VPD in grafts +PRP and grafts +PRP
+membrane, ﬁve articles’ sample data were available for each
of X ̄grafts + PRP and X ̄grafts + PRP+membrane. The
t statistic value t=4.60 with p value <0.0001 suggested that
we may reject null hypothesis in favour of μgrafts + PRP
at α=5%.
When comparing VCAL in “grafts +PRP” and “grafts
+ PRP+membrane,” two articles’ sample data were available
for X ̄grafts + PRP and ﬁve articles’ data for X ̄grafts + PRP
+membrane. The t statistic value t=2.86with p value= 0.0045
suggested that we may reject null hypothesis in favour of
μgrafts + PRP at α=5%.
When comparing REC in “grafts + PRP” and “Grafts
+PRP+membrane,” two articles’ data were available for
computing X ̄grafts + PRP whereas four available articles
provided values for X ̄grafts + PRP+membrane. The t sta-
tistic value t=8.68 with p value <0.0001 again suggested to
reject null hypothesis in favour of μgrafts +PRP at α=5%.
4.8. Comparison of Clinical Outcomes Regarding the Adopted
Surgical Technique. For VCAL, the mean of the test group,
that is, “coronally placed” (based on test group of seven arti-
cles) was compared with the mean of control group, that is,
“original position” (based on test group of two articles).
For VPD, the mean of the test group, that is, “coronally
placed” (based on test group of seven articles) is compared
with the mean of control group, that is, “original position”
(based on test group of ﬁve articles).
For VCAL, to test the hypothesis H0, μcoronally pla-
ced=μoriginal position, X ̄coronally is computed on the basis
of seven observations/articles and X ̄original is the mean of
two observations/articles. The value of t statistic is calculated
as t=0.16 with p value= 0.3777. So we may accept the null
hypothesis of equality of two means at 0.05 level of
signiﬁcance.
For VPD, to test the hypothesis H0, μcoronally pla-
ced=μoriginal position, X ̄coronally is computed on the
basis of seven observations/articles and X ̄original is the
mean of ﬁve observations/articles. The value of t statistic
t=−1.26 with p value = 0.2071 again leads to accept the
equality of two means at 0.05 level of signiﬁcance.
5. Discussion
The present systematic review was intended to investigate the
controversial results raised from similar papers already pub-
lished and to update those. The objective was to provide a
possible evidence for a better performance of regenerative
surgery in infrabony defects with the adjunctive use of autol-
ogous blood-derived growth factors as PRP or focusing on
the diﬀerent surgical techniques adopted and subsequently
to address future research on the topic.
According to the CONSORT guidelines, our consider-
ation aimed to include only RCTs with a quality assessment
equal or more than 2 according to Jadad classiﬁcation. This
allowed us to include only 15 articles from a starting batch
of 73.
Although we followed a strict selection and the quality
testing of the included studies, a signiﬁcant heterogeneity
was found, leading us to implement other strategies for cate-
gorizations of studies in order to assess and solve it. The
39/73
articles
screened 
21 articles
full text
screening 
34 articles filtered for "Humans", "Clinical Trial"
and "English language" 
(i)
18 articles rejected on abstract reading(ii)
(i) 6 articles rejected on full text: 1 not obtained, 1 not
a RCT, 2 no control group, 2 for missing data or SDs
15 articles
included
(i) 15 articles included in the meta-analysis.
Figure 1: Flow chart of the screening process.
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adopted solutions categorized the studies according to the
treatment in 4 classes (biomodulators, grafts, grafts + resorb-
able membranes, and treatment without materials). It also
categorized it according to the surgical ﬂap approach (coron-
ally placed or replaced).
Another problem was the high number of the studies
that did not provide standard deviations about the pro-
vided outcome values. This matter did not allow us to
consider them in the meta-analysis due to the need of data
regarding the sample variations and of the mean change of
the outcomes from baseline examination to the reassess-
ment after the follow-up.
5.1. Overall Intergroup Analysis. The overall meta-analysis
performed on the main clinical outcomes (VPD, VCAL,
and REC) led us to explore the behaviour of the test
group (PRP added) in favouring a better healing in
infrabony defect.
The reported 95% conﬁdence intervals of 4 main studies
[22, 25, 29, 31] were presenting favourable results for VPD
or VCAL, while not the same for REC. This aspect
would suggest an eﬃcient clinical attachment gain inside
the infrabony defect due to the adjunctive use of PRP as
an appropriate regenerative method. Nevertheless, no
radiographic comparison of the alveolar bone levels
95% C.I. of difference of means (test − control) for VCAL
Pradeep et al. (2012)
Kaushick et al. (2011)
Dori et al. (2009)
Piemontese et al. (2008)
Dori et al. (2008)
Dori F et al. (2008)
Dori et al. (2007)
Okuda et al. (2005)
Hanna et al. (2004)
−1.0 −0.5 0.0 0.5 1.0 1.5 2.0
Figure 2: 95% conﬁdence interval presentation for diﬀerence between means of test group and control group for VCAL, that is, mean
(test)−mean (control).
95% C.I. of difference of means (test − control) for VPD
Pradeep et al. (2012)
Kaushick et al. (2011)
Dori et al. (2009)
Camargo et al. (2009)
Piemontese et al. (2008)
Dori et al. (2008)
Dori F et al. (2008)
Dori et al. (2007)
Okuda et al. (2005)
Camargo et al. (2005)
Hanna et al. (2004)
Camargo PM et al. (2002)
−1.0 −0.5 0.0 0.5 1.0 1.5 2.0 2.5
Figure 3: 95% conﬁdence interval presentation for diﬀerence between means of test group and control group for VPD, that is, mean
(test)−mean (control).
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before and after treatment has been reported or system-
atically assessed, so we cannot provide a precise inter-
pretation about the healing process.
In all the considered studies, the main treatment per-
formed was the combination of a bone graft (HA, DFDBA,
and TCP) with PRP without the use of any barrier or a mem-
brane. The performed surgical procedure was ﬂap reposi-
tioning without any coronal advancement.
5.2. Intragroup Analysis.When comparing the eﬃcacy of dif-
ferent regenerative materials or techniques among them, the
analysis was possible only when considering 2 out of 4 classes
of categorization due to missing data.
The combination of bone grafts with PRP was always
producing better clinical results in terms of CALgain and
pocket reduction than the adjunctive use of membranes after
short- and longer term reassessment.
This ﬁnding is in line with another systematic review on
the same topic [7], which suggested that maybe PRP itself can
act as a barrier due to the dense ﬁbrin network produced after
platelet activation. The adjunctive use of a membrane either
resorbable or not could not allow any interaction between
the chemokines and GFs released in the wound area and
the overlying connective tissue.
When we looked if the grafting material showed any pos-
sible eﬀect, no diﬀerences have been identiﬁed favouring a
speciﬁc category. It is therefore suggested that the grafting
material is acting as a scaﬀold leaving the PRP to execute
the inductive phase of the healing process.
5.3. Adopted Surgical Technique. According to the evidence
of a better performance in CALgain of coronally placed ﬂaps
in the regenerative approach to infrabony defects [34], our
investigation moved to analyse if the adopted surgical tech-
nique or the use of adjunctive PRP could justify the observed
better results in the test groups of selected studies. The
considered surgical approaches were the replacement and
the coronal placement. Due to the assessed high heterogene-
ity, a categorization according to the technique was per-
formed using the test groups (PRP added) of the included
studies. In comparison, the test group was the coronally
advanced ﬂap and the control was the replaced ﬂap.
Although not the same number of articles were reporting
the use of each one, a “t test” was possible considering only 2
main clinical outcomes: VPD and VCAL.
In all cases, no diﬀerences in terms of CAL gain or PPD
reduction between the two adopted techniques have been
highlighted. The blood clot stability was achieved in both
conditions, and the healing process could reasonably happen
due to the presence of the growth factors. Even the recession
reduction could be outlined with the replaced ﬂap as the evi-
dence in the overall analysis regarding REC outcomes has
been suggested [20].
6. Conclusions
We conclude from the data in this systematic review that the
adjunctive use of PRP in the regenerative treatment of infrab-
ony defects can be considered as an aﬀordable technique to
get a better CAL gain and PPD reduction in the surgical
treatment of periodontal infrabony defects. Anyway, the lim-
itations of the provided studies are the lack of baseline data
regarding the defect size and their morphology, the absence
of reports of other relevant clinical outcomes, as the bone ﬁll,
and the heterogeneity between studies.
On the basis of this systematic review, the regeneration/
repair of infrabony defects would favour the use of adding
PRP to a simple surgical repositioned ﬂap technique, like in
the open ﬂap debridement (OFD), with the use of bone grafts
(xenografts, HA, or TCP). No better results would be achiev-
able using combinations with biomodulators (Emdogain) or
membranes, the PRP just would act as a biomodulator itself.
95% C.I. of difference of means (test − control) for REC
Pradeep et al. (2012)
Kaushick et al. (2011)
Dori et al. (2009)
Piemontese et al. (2008)
Dori et al. (2008)
Dori F et al. (2008)
Dori et al. (2007)
Okuda et al. (2005)
−1.0 −0.5 0.0 0.5 1.0
Figure 4: 95% conﬁdence interval presentation for diﬀerence between means of test group and control group for REC, that is, mean
(test)−mean (control).
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In a biological sense, this observation would state for the
biomolecular signalling action between PRP and the sur-
rounding cellular environment that any membrane could
interrupt or modify. The use of bone grafts would state as a
blood clot stabilizer enhancing the osteoinductive properties
of the PRP itself.
7. Future Research/Observations
According to the main reported pitfalls, future studies should
be aimed ﬁrst, designed according to RCT schemes in order
to provide clinical evidences.
A comparison between a surgical ﬂap approach alone and
the adjunctive use of PRP would be needful in order to
explore the role of growth factors alone in periodontal regen-
eration and the healing process, as well as the radiographic
bone level assessment before and after treatment, as they
represent a critical parameter in success assessment.
In order to explore which growth factor would be better
suited in periodontal procedures, a multiple-arm RCT would
be needful comparing PRP with other blood-derived agents
available as well as with the diﬀerent techniques adopted to
deliver it.
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